Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Naveen Yarlagadda (NPI 1396013363)

Field	Value
Entity Type	Individual
Organization	Naveen Yarlagadda
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 6, 2011

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

The provider’s code mix is consistent with an oncology infusion practice: high-revenue oncology biologics (J9271, J9299) appear alongside chemotherapy administration and infusion technique codes (96413, G0498, 96365/96375) and supportive care agents such as J1437 (ferric derisomaltose). This combination of billed drugs and infusion/administration CPTs indicates operations that include both clinic-based infusion and associated outpatient management.

Revenue is highly concentrated in a small set of drugs: the precomputed top 3 Medicare codes account for 74.4% of the provider’s total Medicare revenue, and a single code, J9271, generates 54.9% of Medicare revenue ($860K). That concentration implies financial sensitivity to utilization/pricing changes for pembrolizumab.

This provider is effectively single-payer from a claims perspective: lifetime Medicare revenue is $1.6M while Medicaid revenue is none (no Medicaid billing on file). The absence of Medicaid billing suggests limited Medicaid network exposure and contracting leverage within state Medicaid populations.

Competitive standing varies by drug: J9271 (pembrolizumab) ranks #396 of 1841 nationally (78th percentile) and is at a typical, unremarkable volume relative to peers, while J9299 (nivolumab) ranks #447 of 505 (12th percentile) also at a typical volume, but J1437 (ferric derisomaltose) ranks #43 of 581 (92th percentile) and is notably above typical national volume for that code. These mixed rank signals indicate the provider is a modest national participant for checkpoint inhibitors but a comparatively high-volume user of ferric derisomaltose.

Evaluation-and-management activity shows unusually high complexity for outpatient visits: 99215 appears 496 times for $61K (3.9% of Medicare revenue) and is labeled an extreme outlier (99th percentile, far above typical national volume). That extreme E/M volume suggests heavy management of complex established patients and may reflect ongoing longitudinal oncology care or intensive visit-level management.

The provider bills a meaningful amount of inpatient and observation E/M codes (99233, 99232, 99223) alongside outpatient and infusion services, indicating blended practice settings that include hospital-based follow-up or inpatient participation. Presence of both hospital E/M and clinic infusion codes is consistent with a hematology/oncology workflow that spans clinic infusions and inpatient consultations.

High-volume laboratory and supply activity supports a procedural infusion practice: 36415 (phlebotomy) ranks #1683 of 86467 (98th percentile), 85025 (CBC) ranks #1506 of 32833 (95th percentile), and 80053 (CMP) ranks #1524 of 26416 (94th percentile), while 88185 (flow cytometry) shows typical volume. Frequent lab and phlebotomy billing aligns with the monitoring needs of infusion oncology and iron/erythropoietin therapies.

The provider has an established NPI tenure (NPI enumerated 2011-12-06, ~15 years ago) and a lifetime Medicare revenue footprint of $1.6M, consistent with a longstanding, moderate-scale specialty practice focused predominantly on Medicare patients rather than broad Medicaid participation. This tenure combined with the code mix suggests an experienced oncology clinician operating a focused infusion and management practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

80 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,000	$40	$860K
J9299	Injection, nivolumab, 1 mg	6,460	$20	$155K
J1437	Injection, ferric derisomaltose, 10 mg	8,800	$20	$149.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	500	$120	$61K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,240	$40	$44.6K
J0897	Injection, denosumab, 1 mg	1,980	$20	$37.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	390	$90	$34.1K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	310	$90	$26.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	330	$80	$26.2K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	4,000	$10	$24K

Showing 1–10 of 80

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Naveen Yarlagadda — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

80 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	22	40	20,700	$40	$896.3K
J9299	29	30	15,660	$20	$432.9K
J1569	10	10	2,560	$40	$120.3K
J1437	6	20	6,450	$20	$107.8K
J0897	103	160	2,580	$20	$89.7K
J0885	22	40	4,070	$10	$38K
96413	41	80	380	$90	$36.6K
99214	1,192	4,300	130	$70	$18.8K
88185	9	20	780	$20	$18.5K
99233	206	960	130	$90	$18.2K

Showing 1–10 of 80

Related Providers

Other providers that share a Tax Identification Number (TIN) with Naveen Yarlagadda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Baptist Health Medical Group Inc	KY	Internal Medicine Physician	$0	$27.9M
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Baptist Health Services	AR	Family Medicine Physician	$0	$9.9M
Baptist Medcare, Inc	AR	Emergency Medicine Physician	$0	$8M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
James Keane	AR	Procedural Dermatology Physician	$4.9M	$0
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Harshivinderjit Bains	TX	Ophthalmology Physician	$4.1M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0

Nearby Providers

Other providers in the same ZIP code as Naveen Yarlagadda, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Naveen Yarlagadda — Billing Profile & Reimbursement Data

Sign up for Naveen Yarlagadda — Billing Profile & Reimbursement Data policy alerts

Naveen Yarlagadda — Billing Profile & Reimbursement Data

Sign up for Naveen Yarlagadda — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References